Novartis Abandons Heart Drug After Surprising Failure in Key Study
Novartis AG is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and cardiovascular deaths.
By Fabienne Kinzelmann and Robert Langreth · Bloomberg
Novartis AG is largely abandoning an experimental drug analysts once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and cardiovascular deaths.